ArticleJournal of animal science2026
Provision of porcine milk oligosaccharides to support the weaning transition in nursery pigs fed diets including bovine milk co-products.
Article in Journal of animal science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Milk oligosaccharides (MO) support intestinal, microbial, and immune development in young pigs. However, modern production practices wean pigs at an early age, removing them from their source of MO prior to intestinal and immune maturation. The purpose of this study was to investigate the effects of dietary supplementation of galacto-oligosaccharides (GOS) and 2'-fucosyllactose (FL) on the jejunal mucosa-associated microbiota, intestinal immune signaling, morphology, and growth performance of nursery pigs. Forty-eight pigs (6.8 ± 0.2 kg body weight) weaned at 3-weeks-of-age were allotted into six dietary treatments, using a randomized complete block design, with sex and initial body weight as blocks. Dietary treatments were (1) basal diet; (2) basal diet, with supplemental GOS at 1.5% of the diet; (3) basal diet, with supplemental FL at 0.2% of the diet; (4) basal diet, with GOS and FL at 1.5 and 0.2% of the diet, respectively; (5) basal diet, with GOS at 2.3% of the diet; and (6) basal diet, with FL at 0.3% of the diet. These MO were provided alone or in combination at levels mimicking intake at the end of the suckling period, and at 1.5-fold higher, to observe potential dose-dependent responses. Pigs were fed for 21 days in two phases. On d 21, pigs were euthanized for sampling of jejunal mucosa and jejunal tissue. Data were analyzed using the PROC MIXED of SAS 9.4 and contrasts were used to determine the effects of GOS, FL, and their combination (interaction), in addition to the linear effects of increasing dietary GOS or FL. Increasing levels of GOS and FL linearly decreased (P < 0.05) Shannon and Simpson alpha diversity of the jejunal mucosa-associated microbiota. Supplementation with FL increased (P < 0.05) the absolute abundance of Helicobacter in the jejunal mucosa-associated microbiota, although no dose response was observed. Increasing levels of GOS and FL tended to linearly decrease (P = 0.051 and 0.076, respectively) the gene expression of TLR4. Increasing levels of GOS tended to increase (P = 0.054) and increasing supplementation of FL increased (P < 0.05) the number of Ki-67 proliferative cells in the crypt of the jejunum. Increasing levels of GOS increased (P < 0.05) body weight and average daily gain in the early post-weaning period and tended to increase (P = 0.093) body weight by the end of the experimental period. Notably, increasing levels of GOS, and GOS in combination with FL, improved growth performance, whereas FL alone did not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.